Prospect: information for the patient
Relvar Ellipta 92 micrograms/22micrograms powder for inhalation (single dose)
Relvar Ellipta 184 micrograms/22micrograms powder for inhalation (single dose)
furoate of fluticasone/vilanterol
Read this prospect thoroughly before starting to use this medication, as it contains important information for you.
Step-by-step usage instructions
Relvar Ellipta contains two active ingredients: fluticasone furoate and vilanterol. There are two different concentrations of Relvar Ellipta: fluticasone furoate 92 micrograms/vilanterol 22 micrograms and fluticasone furoate 184 micrograms/vilanterol 22 micrograms.
The 92/22 micrograms concentration is used for the regular treatment of chronic obstructive pulmonary disease (COPD) in adults, as well as for the treatment of asthma in adults and adolescents 12 years of age and older.(COPD)in adults, as well as for the treatment of asthma in adults and adolescents 12 years of age and older.
The 184/22 micrograms concentration is used for the treatment of asthma in adults and adolescents 12 years of age and older.
The 184/22 micrograms concentration is not approved for the treatment of COPD.
Relvar Ellipta should be used every day and not only when you have difficulty breathing or other symptoms of asthma and COPD. It should not be used to relieve a sudden attack of choking or wheezing.. If you have this type of attack, use a rescue inhaler with quick action (such as salbutamol). Contact your doctor if you do not have a quick-action rescue inhaler.
Fluticasone furoate belongs to a group of medicines called corticosteroids, often simply called steroids. Corticosteroids reduce inflammation. They also reduce swelling (inflammation) and irritation of the small airways in the lungs and gradually alleviate respiratory problems. Corticosteroids also help prevent asthma attacks and the worsening of COPD.
Vilanterol belongs to a group of medicines called long-acting bronchodilators. It acts by relaxing the muscles of the small airways in the lungs. This helps to open the airways and facilitate the entry and exit of air from the lungs. When used regularly, it helps to keep the small airways of the lungs open.
The regular use of these two active ingredients together will help you control your respiratory difficulties, more than either of the medicines alone.
Asthma,is a chronic severe lung disease in which the muscles surrounding the smaller airways constrict (bronchoconstriction) and become swollen and irritated (inflammation). Symptoms come and go and include difficulty breathing, wheezing, chest tightness, and coughing. It has been shown that Relvar Ellipta reduces asthma attacks and symptoms.
Chronic obstructive pulmonary disease (COPD), is a chronic severe lung disease in which the airways become inflamed and thickened. Symptoms include difficulty breathing, coughing, chest discomfort, and coughing with mucus. Relvar Ellipta has been shown to reduce the exacerbations of symptoms that accompany COPD.
Do not use Relvar Ellipta
Warnings and precautions
Consult your doctor before starting to use Relvar Ellipta:
Consult your doctorbefore using this medication if you think any of the above conditions apply to you.
While using Relvar Ellipta
Immediate breathing difficulties
If you experience chest tightness, cough, wheezing, or difficulty breathing immediately after using your Relvar Ellipta inhaler:
stop using this medicationand seek medical attention immediately, as you may have a serious condition called paradoxical bronchospasm.
Pulmonary infection
If you are using this medication for COPD, you may be at a higher risk of developing a lung infection called pneumonia.See section 4 for information on symptoms to watch for while using this medication.Consult your doctor as soon as possible if you develop any of these symptoms.
Children and adolescents
Do not administer this medication for asthma treatment in children under 12 years old, or for COPD treatment in children and adolescents of any age.
Other medications and Relvar Ellipta
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. Consult your doctor or pharmacist if you are unsure what is in your medication.
Some medications may affect the way this medication works, or make it more likely that you will experience side effects. These include:
Consult your doctor or pharmacistif you are taking any of these medications.
Some medications may increase the effects of Relvar Ellipta, so your doctor may perform regular checks if you are taking these medications.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor before using this medication. If you are pregnant, do not use this medication unless your doctor tells you to.
The safety of this medication during pregnancy and breastfeeding has not been established.Consult your doctorbefore using Relvar Ellipta if you are breastfeeding. If you are breastfeeding, do not use this medication unless your doctor tells you to.
Driving and operating machinery
It is unlikely that this medication will affect your ability to drive or operate machinery.
Relvar Ellipta contains lactose
If your doctor has told you that you have a lactose intolerance, consult with them before using this medication.
Follow exactly the administration instructions of this medication as indicated by your doctor.In case of doubt, consult with your doctor or pharmacist.
Asthma
Recommended dosein the treatment of asthma is one inhalation (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) once a day, administered at the same time every day.
If you have severe asthma, your doctor may decide that one inhalation of the inhaler containing the highest concentration (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol) be administered. This dose is also used once a day, at the same time every day.
COPD
Recommended dosein the treatment of COPD is one inhalation (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) once a day, administered at the same time every day.
The highest concentration of Relvar Ellipta (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol) is not suitable for the treatment of COPD.
Relvar Ellipta is administered by oral inhalation.
Use Relvar Ellipta at the same time every day, as it is effective for 24 hours
It is very important that you use this medication every day, as recommended by your doctor. This will help you not to have symptoms during the day or at night.
Relvar Ellipta should not be used to relieve a sudden attack of choking or wheezing. If you have this type of attacks, use a rescue inhaler with quick action (such as salbutamol).
If you feel short of breath or have wheezing more frequently than usual, or if you are using your rescue inhaler with quick action more often than usual, see your doctor.
How to use Relvar Ellipta
To get the complete information, read the "Step-by-Step Instructions for Use" included after section 6 of this leaflet.
Relvar Ellipta is only administered by oral inhalation.No special preparation of Relvar Ellipta is required, not even the first time it is to be used.
If symptoms do not improve
If symptoms (choking, wheezing, coughing) do not improve or worsen, or if you are using your rescue inhaler with quick action more often than usual:contact your doctor as soon as possible.
If you use more Relvar Ellipta than you should
If you accidentally inhale more Relvar Ellipta than recommended by your doctor, consult with your doctor or pharmacist. If possible, show them the inhaler, the package or this leaflet. You may notice that your heart beats faster than usual, feel shaky or have a headache.
If you have used more medication than indicated for a prolonged period, it is especially important that you receive advice from your doctor or pharmacist. This is because higher doses ofRelvar Ellipta may reduce the amount of naturally produced hormones by your body.
If you forgot to use Relvar Ellipta
Do not inhale a double dose to compensate for the missed doses.Take the next dose at your usual time.
If you have wheezing or choking, or develop any other symptoms of an asthma attack,use your rescue inhaler with quick action(such as salbutamol), and seek medical advice.
Do not stop using Relvar Ellipta without consulting
Use this medication for the time recommended by your doctor. It will only be effective for the time you continue to use it. Do not stop using it until your doctor tells you to, even if you feel better.
If youhaveanydoubts about the useof this medication, ask yourdoctor, pharmacist ornurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Allergic reactions
Allergic reactions are rare (they can affect up to 1 in 1,000 people)
If after taking Relvar Ellipta, you experience any of the following symptoms, stop using this medicine and contact your doctor immediately:skin rash(hives)or redness
Immediate breathing difficulties
Immediate breathing difficulties after using Relvar Ellipta are rare.
If your breathing or wheezing worsens immediately after using this medicinestop using itandseek medical helpimmediately.
Pneumonia (lung infection)in patients with COPD (a frequent side effect, which can affect up to 1 in 10 people).
If you experience any of the following symptoms while using Relvar Ellipta,consult your doctor. They could be symptoms of a lung infection:
Other side effects:
Very frequent side effects
Can affect more than 1 in 10 people:
Frequent side effects
Can affect up to 1 in 10 people:
Rare side effects
Can affect up to 1 in 100 people:
Rare side effects
Can affect up to 1 in 1,000 people
Reporting side effects
If you experienceany type of side effect, consult your doctor or pharmacist, even if it is apossibleside effect that does not appear in this leaflet.You can also report them directly through thenational notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging, tray, and inhaler after CAD. The expiration date is the last day of the month indicated.
Keep the inhaler inside the sealed tray to protect it from moisture and only remove it immediately before the first use. Once the tray is opened, the inhaler can be used for a period of 6 weeks, counting from the date the tray is opened.Write the date when the inhaler should be discardedin the designated space on the label. The date should be noted as soon as the inhaler is removed from the tray.
Do not store at a temperature above 25°C.
If you store it in the refrigerator,let the inhaler return to room temperature for at least one hourbefore using it.
Medications should not be disposed of through drains or trash.Ask your pharmacist how to dispose ofthe packaging and medications that you no longerneed.This will help protect the environment.
Composition of Relvar Ellipta
Appearance of the product and contents of the pack
Relvar Ellipta is a powder for inhalation (single-dose).
The Ellipta inhaler is formed by a greyish-coloured inhaler with a yellow mouthpiece protector and a dose counter.It is packaged in a laminated aluminium blister pack with a foldable aluminium lid.The blister pack contains a desiccant to reduce humidity in the pack.Once the lid of the blister pack is opened, remove the desiccant, do not ingest or inhale it.The inhaler does not need to be conserved and the laminated aluminium blister pack once opened.
Relvar Ellipta is available in packs containing 14 or 30 doses (for a 14 or 30-day treatment) and in clinical packs of 90 doses (3 inhalers of 30 doses, for a 90-day treatment).Only some pack sizes may be marketed.
Marketing authorisation holder:
GlaxoSmithKline (Ireland) Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
Responsible for manufacturing:
Glaxo Wellcome Production
Zone Industrielle No.2
23 Rue Lavoisier
27000 Evreux
France
Further information on this medicinal product can be obtained by contacting the local representative of the marketing authorisation holder:
België/Belgique/Belgien GlaxoSmithKline Pharmaceuticals s.a./n.v. Tel/Tel:+ 32 (0) 10 85 52 00 | Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC” Tel:+370 52 691 947 | |
Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals s.a./n.v. Belgique/Belgien Tél/Tel:+ 32 (0) 10 85 52 00 | ||
Ceská republika GlaxoSmithKline s.r.o. Tel: + 420 222 001111 | Magyarország Berlin-Chemie/A. Menarini Kft. Tel.:+36 23501301 | |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 | Malta GlaxoSmithKline (Ireland) Limited Tel: +356 80065004 | |
Deutschland BERLIN-CHEMIE AG Tel: +49 (0) 30 67070 | Nederland GlaxoSmithKline BV Tel: + 31 (0)33 2081100 | |
Eesti OÜ Berlin-Chemie Menarini Eesti Tel: +372 667 5001 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 | |
Ελλ?δα Menarini Hellas A.E. Τηλ: +30 210 83161 11-13 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 | |
España GlaxoSmithKline, S.A. Tel: + 34 900 202 700 | Polska GSKServicesSp. z o.o. Tel.: + 48 (0)22 576 9000 | |
France Laboratoire GlaxoSmithKline Tél.: + 33 (0)1 39 17 84 44 Hrvatska Berlin-Chemie Menarini Hrvatska d.o.o. Tel:+385 1 4821 361 | Portugal GlaxoSmithKline – Produtos Farmacêuticos, Lda.Tel: + 351 21 412 95 00 România GlaxoSmithKline (Ireland) Limited Tel: +40 800672524 | |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o. Tel: +386 (0)1 300 2160 | |
Ísland Vistor hf. Sími: + 354 535 7000 | Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o. Tel:+421 2 544 30 730 | |
Italia GlaxoSmithKline S.p.A. Tel: + 39 (0)457741111 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 | |
Κ?προς GlaxoSmithKline (Ireland) Limited Τηλ: +357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 | |
Latvija SIA Berlin-Chemie/Menarini Baltic Tel:+371 67103210 | United Kingdom (Northern Ireland) GlaxoSmithKline (Ireland) Limited Tel: + 44 (0)800 221441 | |
Last update of this leaflet:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Step-by-step instructions for use
What is the Ellipta inhaler?
The first time you use Relvar Ellipta, you do not need to check that it works correctly, it is already ready to be used. Just follow these step-by-step instructions.
Your Relvar Ellipta inhaler box contains:
The inhaler is packagedin ablister pack.Do not open the blister pack until you are ready to start using your new medicine. When you are ready to use your inhaler, remove the lid to open the blister pack. The blister pack containsa desiccant, to reduce humidity in the pack.Remove the desiccant, do not open it, ingest it or inhale it.The inhaler does not need to be conserved and the laminated aluminium blister pack once opened.
When you take the inhaler out of the blister pack,it will be in the “closed” position.Do not open the inhaleruntil you are ready to inhalea dose of the medicine.When the blister pack is opened, note the date of “Dispose of” in the space provided on the inhaler label. The date of “Dispose of” is 6 weeks from the date of opening the blister pack. After this date the inhaler should not be used any more. The blister pack can be disposed of after the first opening.
If you store it in the fridge, let the inhaler reach room temperature for at least one hour before use.
The step-by-step instructions for use of the Ellipta inhaler for 30 doses (30-day treatment) also apply to the Ellipta inhaler for 14 doses (14-day treatment).
If you open and close the lid without inhaling the medicine, you will lose the dose.
The lost dose will be retained safely inside the inhaler, but it will not be available to be inhaled.
You cannot accidentally administeran additional doseor a double dose by inhaling.
Before opening the lid, wait until you are ready to inhale a dose. Do not shake the inhaler.
The medicine is now ready to be inhaled.
As confirmation, the dose counter decreases by1unit.
You may not be able to taste or notice the medicine, even when you use the inhaler correctly.
If you want to clean the mouthpiece, use adry cloth beforeclosing the lid.
This will make it less likely to cause side effects such as mouth or throat ulcers.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.